Apellis Pharmaceuticals Inc (APLS) Stock Analysis

Apellis Pharmaceuticals Inc (APLS) is a publicly traded company in the HEALTHCARE sector. It trades at $41.03. This page summarizes the public market data, fundamentals, and frequently asked questions for APLS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $41.03

Market Sentiment

Apellis Pharmaceuticals Inc currently has a Bullish sentiment score of 0.17.

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc. is a forward-looking clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focusing on the development of novel therapeutic compounds targeting the complement system to treat autoimmune and inflammatory diseases. The company's innovative pipeline, underscored by its flagship asset, aims to revolutionize treatment options for patients with complex conditions, highlighting Apellis' commitment to delivering transformative therapies. As a signific...

GNG Research Analysis

GNG Research scores Apellis Pharmaceuticals Inc (APLS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for APLS.

Frequently Asked Questions

Does APLS pay dividends?

Apellis Pharmaceuticals Inc (APLS) does not currently pay a regular dividend.